Sunday, May 19, 2013

This page contains the records of free Webinars that Rx-360 has offered previously.  These Webinars are source of educational material discussing various topics pertaining to the pharmaceutical supply chain and quality.

Illegal Diversion of Pharmaceuticals: How should we tackle this increasing threat to patient safety? Minimize
    

Free Webinar: Illegal Diversion of Pharmaceuticals

Tuesday, May 14, 2013
11:00 AM - 12:00 PM EDT

To Register go to
www4.gotomeeting.com/register/412123671

As part of its ongoing educational webinar series designed to further best practices for supply chain security, Rx-360 members will address the topic of illegally diverted pharmaceuticals. Illegal diversion is a nebulous issue with grave consequences: a complex combination requiring well thought-out and proven mitigation strategies. This webinar will contextualize the causes and impact of illegal diversion with case studies specific to this issue. Successful mitigation strategies for illegal diversion within the global pharmaceutical supply chain will be highlighted. 

Webinar content is derived from the recently released Illegal Diversion of Pharmaceuticals whitepaper, authored by Rx-360 members from Merck & Co, Amgen, Astra Zeneca, Bristol-Myers Squibb, Genentech, Takeda, Biogen Idec and Johnson & Johnson.

 

Please click here to register for a free educational webinar on Illegal Diversion of Pharmaceuticals on May 14, 2013

 

More information regarding the topics covered in the Rx-360 Illegal Diversion of Pharmaceuticals whitepaper, by clicking here 

Illegally diverted pharmaceuticals can have a potentially serious patient safety impact, as they have not passed through a controlled and regulated supply chain. By their nature all cases of illegally diverted product have at some point come into contact with the authorized supply chain; therefore, pharmaceutical manufacturers and distributors are well positioned to potentially have a significant impact on this aspect of illegal trade. This paper collates the expertise and experience of a number of organizations and aims to describe some of the principle causes and consequences of illegal diversion as well as practical mitigation strategies that can be adopted.

 

The phenomenon of illegal diversion is driven primarily by arbitrage opportunities created by pricing differentials. Many of these price differences have complex origins that have their foundation in regulations and legislation in particular markets. This paper does not seek to address the subject of pharmaceutical pricing; however, it is important to recognize these price differentials and the role they play in illegal diversion.

Illegal diversion is an issue that can occur within individual markets and between national markets; however, this discussion will focus on illegal diversion that occurs between national markets. This particular risk is rapidly increasing due to the growth of complex and interconnected global commerce. The goal of this paper is to provide a compendium of information regarding illegal diversion: an overview of the supply chain and marketplace vulnerabilities contributing to illegal diversion, the impact of this problem and illegal diversion mitigation strategies that have been successfully deployed by pharmaceutical manufacturers. 

Please clicking here to access the full text of the Illegal Diversion of Pharmaceuticals whitepaper.

 

  

Incident Management Minimize

To View or Download the Webinar 
Click on the Slide Below

  

Rx-360 Informational Webinar (Non YouTube) Minimize

To View or Download the Webinar 
Click on the Slide Below

  

European Falsified Medicines Directive (Non YouTube) Minimize

To View or Download the Webinar
Click on the Slide Below

  

European Falsified Medicines Directive (YouTube) Minimize
image
Video Gallery
Falsified Medicines Directive
Falsified Medicines Directive
  

 

2009 © Rx-360